In this issue of *Diabetes*, Grey and colleagues ([@B1]) demonstrate that therapeutic B-cell depletion delays diabetes onset and reduces diabetes incidence in NOD mice. B-cell depletion in pre-diabetic NOD mice was accomplished using an extended regime of recombinant B-cell maturation antigen (BCMA)-Fc chimerized protein that targets B-lymphocyte stimulator (BLyS)/B-cell--activating factor of the tumor necrosis factor family (BAFF)---a cytokine critical for maintenance of the peripheral B-cell pool. This follows recent studies demonstrating significant effects of B-cell depletion on diabetes onset and severity ([@B2][@B3][@B4]--[@B5]); however, no other studies have reported profound and complete protection from hyperglycemia as observed here. Following B-cell depletion therapy during 9--15 weeks of age, NOD mice remained diabetes free for ≥50 weeks of age, even after B-cell reconstitution. An increase in CD25^+^Foxp3^+^CD4^+^ regulatory T-cells (Tregs) following B-cell depletion may mediate prolonged tolerance given that the CD25 monoclonal antibody (mAb) treatment neutralized the long-term therapeutic benefits of B-cell depletion ([Fig. 1](#F1){ref-type="fig"}). This mechanism may explain why B-cell--deficient NOD.μMT mice do not develop hyperglycemia given that autoimmune diabetes was also precipitated in these mice by Treg depletion.

![Model for autoantigen presentation in B-cell--depleted NOD mice. Autoantigen presentation is normally balanced between B-cells and dendritic cells (DCs) in mice ([@B16]). *A*: NOD autoantigen presentation. However, B-cell cognate presentation of pancreatic autoantigens may dominate in NOD mice because B-cell selection ([@B17]) and innate cell APC function are impaired ([@B18]). As a result, B-cell--driven pathogenic CD4^+^ T-cell expansion and effector function leads to β-cell destruction and insulin deficiency. *B*: Presentation without B-cells. Mature B-cell depletion in NOD mice eliminates the initiating role of B-cells in disease pathogenesis but shifts antigen presentation to other APCs that may reduce CD4^+^ T-cell activation in favor of Treg induction or expansion and lead to a tolerogenic state or honeymoon period without disease. *C*: Following B-cell reconstitution, previously induced Tregs may limit autoreactive T-cell activation and expansion, thereby enforcing long-term tolerance and protection from diabetes onset. Teff, effector T-cell.](zdb0070957820001){#F1}

Most diabetes-modifying immunotherapies target the T-cell compartment directly because β-cell destruction is primarily mediated by CD4^+^ and CD8^+^ T-cells. Examples include T-cell depletion, blockade of T-cell costimulation, and Treg induction. Therapies that reduce antigen-specific T-cell clonal expansion have profound effects during the pre-diabetic stages of disease, whereas few therapies reverse disease once the clinical manifestations of diabetes are evident. This limitation appears to hold for B-cell--directed therapies in NOD mice as well. Genetically, B-cell--deficient NOD mice generally lack islet infiltration or insulitis and are free of overt diabetes ([@B6][@B7][@B8]--[@B9]). Likewise, B-cell depletion by anti-μ antibody given from birth abrogates insulitis development in NOD mice ([@B10]). Recent B-cell depletion studies in NOD mice have included an anti-BLyS/BAFF mAb ([@B3]), anti-mouse CD20 mAb ([@B2]), anti-human CD20 mAb in human CD20 transgenic NOD mice ([@B4]), and anti-CD22 immunotoxin ([@B5]), which all target mature B-cells. While each study highlights particular findings or interpretations, the main observation is that the absence of B-cells alters an early trigger for diabetes onset, with the consistent conclusion that disease does not progress in the absence of B-cells. Whether the remarkable long-term tolerance indicated in the current study results from features unique to the BCMA-Fc chimerized protein is difficult to conclude because all of the reported B-cell depletion strategies have varied in approach, timing, and analysis among individual NOD mouse colonies. Nonetheless, now that B-cell depletion strategies with potential clinical efficacy have been found, standardized guidelines for side-by-side comparisons in NOD mice should be developed to identify important differences between therapeutic approaches and results.

B-cells are among the earliest cells to infiltrate the pancreatic islets of NOD mice, and autoantibodies against islet antigens indicate disease onset in humans and mice ([@B11]). Despite this, autoantibody production is not sufficient to initiate disease and is disconnected from the occurrence of diabetes and insulitis ([@B11]). Rather, B-cells are multifunctional and are crucial antigen-presenting cells (APCs) for priming proinflammatory T-cell responses to β-cell antigens ([@B12][@B13][@B14][@B15]--[@B16]). Thereby, obligatory B-cell APC function may set the stage for systemic autoreactivity in NOD mice because B-cell selection ([@B17]) and innate cell APC function are impaired ([@B18]) in NOD mice ([Fig. 1](#F1){ref-type="fig"}). Consistent with this, diabetes resistance in congenitally B-cell--deficient NOD mice is lost following B-cell reconstitution ([@B9],[@B12]). It is encouraging that the return of B-cells following prolonged depletion in the current study did not alter diabetes resistance given that the effect of mature B-cell depletion on the peripheral B-cell repertoire remains an open question. Presumably, unselected and potentially autoreactive pre--B-cells and immature B-cells that were not depleted during therapy repopulate the periphery. For this, pre--B-cell and B-cell depletion using CD19-directed therapies may have advantages ([@B19]). Because regulatory B-cells (B10-cells) also significantly affect autoimmunity ([@B20]), it will be important to determine whether they represent a significant component of the reconstituted B-cell pool. Nonetheless, B-cell depletion before disease onset may induce long-term tolerance through Tregs---a possibility that opens new avenues for investigation.

Transient B-cell depletion after the first signs of disease onset using anti-BLyS mAb also arrests diabetes progression and maintains NOD mice in a "honeymoon" state for extended periods ([@B3]). Because Treg numbers did not change 10 weeks posttreatment, the honeymoon was attributed to enhanced B-cell competition and selection as a result of limited BLyS/BAFF availability. However, that other B-cell depletion therapies similarly reduce diabetes incidence ([@B2],[@B4],[@B5]) argues that immediate β-cell protection results from changes in available APCs for autoreactive T-cell activation, where APC--T-cell interactions may also induce Treg expansion beyond that of pathogenic effector T-cells ([Fig. 1](#F1){ref-type="fig"}). Future studies are needed to determine whether B-cell depletion uniformly induces Tregs and how. The effect of BCMA-Fc treatment during later stages of insulitis will also require further examination. If Tregs do accumulate as suggested by Grey and colleagues, B-cell depletion may be curative when administered before extensive loss of pancreatic β-cell function because immune regulatory mechanisms will not be beneficial once β-cell destruction is complete, except for subsequent islet transplants.

In summary, "Plan A" has shown that B-cell depletion is a powerful therapeutic tool for reducing diabetes severity and arresting islet destruction in NOD mice. This advance in understanding diabetes onset and progression provides the basis for "Plan B": identifying the optimal strategy for targeting B-cells for therapeutic benefit. Whether this involves the modulation of APC--T-cell interactions, the induction of regulatory B- and T-cell subsets, or both remains unanswered. Given the demonstrated importance of both T- and B-cells in diabetes initiation and pathogenesis, it is likely that modulating both arms of the adaptive immune response will be key for the development of protective immunotherapies.
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